In-ovo vaccination in commercial broilers is a growing trend worldwide due to the advance it represents in the automation of the vaccination process. The large production volumes managed by broiler hatcheries and the advantage of individual vaccination and dosage make this route of administration the most preferable under current management conditions.

Additionally, in line with the One Health strategy for reducing antimicrobial resistance, the use of vaccines against coccidiosis in commercial broilers is increasing due to their ability to reduce resistance and to control the Eimeria field challenge. 

As a result, new vaccines against avian coccidiosis, attenuated by precociousness, specifically developed for in-ovo administration, are becoming a good option for the control of this disease.

The objective of this scientific Challenge is to showcase the performance of attenuated coccidiosis vaccines administered through in-ovo injection on commercial broiler farms by means of field data (hereinafter the "Data Trial"). 

The top 3 Data Trials will be selected for submission as abstracts at the 2024 AAAP Annual Meeting¹. The author/s of each selected trial will be rewarded with the opportunity to attend the event, which will take place in July 2024 in the city of St. Louis (USA), as presenters (either through a poster or an oral presentation).
 

The Challenge is open to avian veterinary surgeons, practitioners and/or other professionals.

Any questions in connection with the Challenge shall be addressed to corporate.poultry@hipra.com indicating as subject CHALLENGE IN-OVO COCCIDIOSIS VACCINATION.

References

^{1  https://www.aaap.info/future-annual-meetings}